Key Takeaways
- • Temple View Capital secured a strategic partnership with Oaktree through its Asset-Backed Finance strategy, including a significant forward capital commitment and strategic investment to support the private lending platform's growth.
- • TVC has originated over $5 billion in residential transition loans since its 2017 founding, specializing in ground-up construction, fix-and-flip, bridge, and DSCR loan products for professional real estate investors.
- • The partnership strengthens TVC's diversified funding strategy across bank financing, institutional investor capital, and its rated residential transition loan securitization shelf, enhancing lending capacity and institutional capital base diversification.
- • Oaktree's investment signals confidence in TVC's nine-year-old platform and enables continued investment in technology, operational infrastructure, and talent to deliver consistent performance across market cycles.
Summary
Temple View Capital announced a strategic partnership with Oaktree on July 15, 2026, establishing a long-term relationship designed to accelerate the growth of TVC's private lending platform. The transaction includes a significant forward capital commitment and strategic investment from Oaktree through its Asset-Backed Finance strategy, reinforcing TVC's position as a leading national private lender focused exclusively on residential real estate investors.
Since its inception in 2017, Temple View Capital has originated more than $5 billion in residential transition loans for professional real estate investors across the United States. The company operates a comprehensive lending platform that encompasses ground-up construction financing, fix-and-flip loans, bridge loans, and DSCR (Debt Service Coverage Ratio) loan products. TVC maintains an active rated residential transition loan securitization platform, providing consistent access to institutional capital markets and supporting the company's scalable funding infrastructure.
The partnership with Oaktree strengthens TVC's diversified funding strategy, which previously included bank financing relationships, institutional investor capital sources, and its residential transition loan securitization shelf. According to Steven Trowern, Co-Founder of Temple View Capital, the investment represents "a strong endorsement of the platform we have built over the past nine years." The capital infusion is designed to support expanded lending capacity, further diversify the institutional capital base, and fund continued investment in technology, operational infrastructure, and talent development. These enhancements underscore TVC's commitment to delivering high-quality service to clients and maintaining consistent performance across varying market cycles.
Since its inception in 2017, Temple View Capital has originated more than $5 billion in residential transition loans for professional real estate investors across the United States. The company operates a comprehensive lending platform that encompasses ground-up construction financing, fix-and-flip loans, bridge loans, and DSCR (Debt Service Coverage Ratio) loan products. TVC maintains an active rated residential transition loan securitization platform, providing consistent access to institutional capital markets and supporting the company's scalable funding infrastructure.
The partnership with Oaktree strengthens TVC's diversified funding strategy, which previously included bank financing relationships, institutional investor capital sources, and its residential transition loan securitization shelf. According to Steven Trowern, Co-Founder of Temple View Capital, the investment represents "a strong endorsement of the platform we have built over the past nine years." The capital infusion is designed to support expanded lending capacity, further diversify the institutional capital base, and fund continued investment in technology, operational infrastructure, and talent development. These enhancements underscore TVC's commitment to delivering high-quality service to clients and maintaining consistent performance across varying market cycles.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.